S1PR1 and myeloid sarcoma: While disease modifying therapy (DMT) treatment in RRMS is more effective, those approaches have been less successful at reducing progression in progressive forms of MS, as shown e.g. with the negative trial using the sphingosine-1-phosphate receptor (S1PR) modulator fingolimod4.